NRC Health: Record Contract Value, a GAAP Loss, and the Qualtrics Shadow
TRCV up 11% and the best Governance Institute bookings in seven years — while operating income swung to -$5M and the stock is still 72% below its 2020 high.
NRC · Earnings Call · 2026-10-27
A record booking quarter that hasn't reached the P&L yet
On the number NRC Health actually steers by, this was the quarter the entire bull case rests on. Total recurring contract value finished at $151.9 million, up 11% year over year — TRCV growth of the double-digit variety management has been pointing investors toward for several quarters — with experience contract value up in the mid-teens, and the Governance Institute delivering its strongest bookings in seven years while growing contract value nearly 10%. Then came the reported numbers. Revenue of $35 million, up 4% year over year and 2% sequentially — and roughly two points of the gap versus TRCV is arithmetic, not demand. NRC replaced a third-party vendor inside several reputation-monitoring SKUs, and the new arrangement flips those lines from gross to net: “This was due to the strategic replacement of a third party vendor for some elements of these solutions, where the new arrangement requires net revenue accounting” — Shane R. Harrison, Chief Financial Officer · 2026-10-27. The accounting change costs about $1.5 million a year, hits hardest in Q2, and fades in the back half without touching cash. It also means the 11%-to-4% gap is partly definitional, because contract value is still booked gross — as the CFO put it, “the policy is a gross treatment. So we did not adjust TRCV” — Shane R. Harrison, Chief Financial Officer · 2026-10-27. Below that line the split widens. Adjusted EBITDA was $9.4 million at a 27% margin, flat sequentially but down three points and $900,000 year over year as NRC staffed delivery and customer success ahead of its largest implementation. GAAP is harsher: operating income of -$5 million, an operating margin of -12.8%, down 17.5 points year over year. Most of the bridge is stock compensation: the add-back ballooned to $7 million from near zero after NRC accelerated vesting on 2023 restricted grants for three executives and paid their personal taxes in cash. That is about 20% of quarterly revenue. Strip it out and adjusted EPS is $0.31; keep it in and free cash flow less stock comp is -$7 million.Qualtrics bought the biggest competitor, and the buyers blinked
The genuinely new thing on this call was competitive, not financial. Qualtrics closed its acquisition of Press Ganey on May 18. “The early effect is this has caused some customers who are inactive RFP processes to pause and reassess” — Trent Green, Chief Executive Officer · 2026-10-27, the CEO said — two live processes had been NRC versus Qualtrics versus Press Ganey, and post-close the latter two can bid jointly. Qualtrics appears nowhere in NRC's prior keyword history; it lands here as a top gainer, and with it a phrase the company has not used before: an era of buyer uncertainty. The translation into selling metrics is explicit. Average deal size in the pipeline is down, because the organizations coming to market are smaller while bigger ones wait; “our pipeline is up 60% higher than it was the same quarter last year” — Constantine Davides, Analyst · 2026-10-27. More proposals, smaller cheques, longer pauses. NRC's counter-positioning is certainty — a platform that already exists, against a competitor that has not told customers what its migration path looks like — plus the Governance Institute as a CEO-level door-opener in a business that is only about a tenth of revenue, and a base where roughly 70% of customers still buy a single product.I do see this as temporary. Do not have crystal balls to how long this is gonna be before the market has greater clarity.
AI as a feature, not a SKU
NRC's product story is the AgenTeq AI ambient-listening capability now embedded in its rounding platform: a frontline leader talks to a patient, the model transcribes, summarises, flags service-recovery moments and drafts documentation. It is a real differentiator in a narrow lane, and the first analyst question was whether it is monetisable. The answer was no — “we do not presently have an AI skew for our AgenTeq tool that is embedded in our in our rounding product” — Trent Green, Chief Executive Officer · 2026-10-27 — with AI framed as win-rate and retention support today, and as a cost-to-serve lever inside implementation and support later.That is a defensible position and an unexciting one for a $481 million company whose shares trade at 3.4x revenue, a multiple 73% below its 2019 peak. It is also a mirror image of the tape: the market's AI data center complex is down more than 5% over 90 days with nearly fifty decliners, punished for exactly the capital intensity NRC avoids. Here the AI narrative is free; it just does not print revenue.Our objective is not simply to apply AI to health care. it is to apply AI to 1 of health care's most differentiated datasets.